Exhibit 99.2

# NEWS RELEASE

---

FOR 3:00 P.M. CT RELEASE
April 29, 2004

|Contact:                |                              
|----------------------- | -----------------------------
|Sam Reinkensmeyer       | Shawn Brumbaugh/Marian Briggs
|Chief Financial Officer | Padilla Speer Beardsley Inc. 
|CNS, Inc.               | (612) 455-1700               
|(952) 229-1500          | sbrumbaugh@psbpr.com         
|sreinkensmeyer@cns.com  | mbriggs@psbpr.com            
|Nasdaq Symbol:   CNXS   |                              

# CNS, Inc. Reports Strong Fiscal 2004 Results

| |   Full year net sales up 10%
  Operating income for the year rises 32%
  Fourth quarter earnings per share of 2 cents exceed companys updated guidance
  Company provides fiscal 2005 outlook
| | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MINNEAPOLIS,
April 29  CNS, Inc. (Nasdaq: CNXS), the Breathe Right® company, today
announced results for the fiscal year and fourth quarter ended March 31, 2004.

For
the full year 2004, CNS net sales grew 10 percent to a record $87.0 million versus
$79.1 million in fiscal 2003. Net income in fiscal 2004 was $8.5 million, or $0.59 per
fully diluted share, up 31 percent compared to prior-year net income of $6.5 million, or
$0.46 per fully diluted share.

In
the 2004 fourth quarter, net sales rose 6 percent to $22.5 million versus $21.3 million in
the prior-year period. Net income for the fourth quarter was $341,000, or $0.02 per fully
diluted share, compared to $569,000, or $0.04 per fully diluted share, in the same
period last year. Fourth quarter earnings per fully diluted share of $0.02 exceeded the
companys updated estimates provided on March 8, 2004, primarily due to lower levels
of trade promotion spending and reduced operating expenses.

Gross
margins rose 2 percentage points for both the 2004 fiscal year and fourth quarter.
Operating expenses increased during the 2004 full year and fourth quarter by 9 percent and
11 percent, respectively, as a result of expanded advertising and promotion to support the
Breathe Right and FiberChoice® product lines.

---

CNS, Inc. Reports Fiscal 2004 Results
Page 2

We
are pleased to report 10 percent net sales growth for the year and a 28 percent increase
in annual earnings per share, despite the early end to the cold and flu season in
mid-January, which negatively impacted sales of Breathe Right products in the fiscal
fourth quarter, said Marti Morfitt, president and chief executive officer, CNS, Inc.
During the fourth quarter, we experienced continued strong sales of FiberChoice and
incremental growth in Breathe Right nasal strips. While sales of Vapor Shot! came in
below our expectations for its first year, jointly promoting mentholated vapor strips and
Vapor Shot! proved to be a successful strategy and helped drive higher mentholated vapor
strip sales.

CNS
continued to report strong cash flow in fiscal 2004, generating $8.6 million of operating
cash flow. The company ended the year with $49.4 million in cash and marketable
securities. During fiscal 2004, CNS initiated a quarterly cash dividend of $0.04 per
share, and yesterday announced a 25 percent increase in the quarterly dividend to $0.05
per share, payable on June 4, 2004 to shareholders of record as of May 21, 2004.

Fourth Quarter and Fiscal-Year Product Results

        Domestic Breathe Right sales
in the 2004 fourth quarter totaled $16.0 million versus $15.9 million in the
prior-year period, as growth in Breathe Right nasal strips was offset by lower
sales of Breathe Right Snore Relief throat spray. For the 12 months, sales
of domestic Breathe Right brand products grew 11 percent to $64.1 million
compared to $57.9 million in the year-ago period.

International
sales of Breathe Right strips in the 2004 fourth quarter rose 11 percent to $3.5 million
compared to $3.1 million in the prior-year quarter. Full-year international sales totaled
$13.0 million compared to $13.8 million last year. Fourth-quarter shipments to the companys
Japanese distributor were in line with expectations, but consumer purchases in Japan fell
far short of expectations in February and March, due to an unusually soft allergy
season. As a comparison, consumer takeaway of over-the-counter rhinitis medications in
Japan during the peak allergy month of March declined 45 percent versus last year, with
consumption of Breathe Right nasal strips down 43 percent for the same period. The weak
consumer takeaway in Japan during the critical allergy months of February and March will
result in higher inventories at our distributor and lower international sales for CNS during fiscal 2005.

Sales
of FiberChoice chewable fiber tablets grew 27 percent to $2.6 million in the fourth
quarter versus $2.0 million in the prior-year period. FiberChoice sales for the full year
rose 31 percent

---

CNS, Inc. Reports Fiscal 2004 Results
Page 3

to $9.3 million compared to
$7.1 million last year. We are very pleased with the increasing
market penetration of FiberChoice, which is growing faster than any other
product in the bulk fiber category, said Morfitt.

During
the fourth quarter, CNS decided to exit its line of Flair equine products. The company
will terminate its agreements with its distributor of Flair products and the licensor of
technology related to this business, effective April 30, 2004. Net sales of Flair products
totaled $313,000 in the fourth quarter and $375,000 for fiscal 2004.

Outlook for Fiscal 2005
        In fiscal 2005, we are
sharpening our focus on expanding the market penetration of Breathe Right nasal
strips in the U.S. and abroad, said Morfitt. As part of this effort,
we will relaunch our Clear nasal strips targeting consumers with sensitive skin
types, building on the recent success of our relaunched mentholated vapor strips
during the past cold and flu season. In addition, we anticipate continued strong
growth of our FiberChoice brand, and we have several potential new products in
development for future introduction.

While
we have demonstrated our ability to drive annual sales growth of 10 percent or
greater, said Morfitt, we view fiscal 2005 as a building
year. Therefore, short-term revenue growth over the next year will be lower
than in fiscal 2004 as we prepare new products for market introduction and build a
solid foundation for future growth. In the meantime, we continue to have a
strong balance sheet with no long-term debt and growing cash flow.

For
the 2005 fiscal year ending March 31, 2005, the company currently anticipates net sales
will grow from 3 to 7 percent to between $90 million and $93 million. Fully diluted
earnings per share in fiscal 2005 are estimated to range between $0.63 and $0.68, an
increase of 7 to 16 percent over fiscal 2004.

Sales
growth during the first half of fiscal 2005 will be lower than the second half of the
year, due to the lack of a new product in fiscal 2005, as well as high inventory levels in
Japan resulting from the recent weak sales volumes associated with the soft allergy
season. CNS sales for the fiscal 2005 first half are expected to be approximately flat
versus the same period last year. Sales for the second half of fiscal 2005 are expected to rise 6 to 11 percent versus
the fiscal 2004 second half.

Advertising
and promotion spending will be phased more evenly and earlier in fiscal 2005 to support
increased allergy usage of nasal strips in the first half of the fiscal year and the
re-launch of

---

CNS, Inc. Reports Fiscal 2004 Results
Page 4

Clear nasal strips in the second
quarter. During the first half of the year, the company will also test a number of
marketing programs designed to accelerate future growth of Breathe Right nasal strips, as
well as increase spending on new product development. As a result, operating profit
growth will be concentrated in the second half of fiscal 2005, with operating profit
declines expected in the first half of the year. Operating profit margins are expected to
be more consistent from quarter to quarter during fiscal 2005 than they have been in
prior years when advertising and promotion expense was more heavily concentrated in the
cold and flu season during the third and fourth quarters.

CNS
expects net sales for the fiscal first quarter ending June 30, 2004, in the range of $17.0
million to $18.0 million, compared to net sales of $17.5 million in the first quarter of
last year. Earnings for the first quarter are estimated between $0.09 and $0.12 per fully
diluted share, versus earnings of $0.20 per fully diluted share in the prior-year period.

Conference Call Webcast

        A conference call to review
the fourth-quarter and full-year results is scheduled today at 4 p.m. CT (5 p.m.
ET). Interested participants may listen to the live conference call or replay
over the Internet by logging onto CNS Web site at www.cns.com. A
replay of the fourth-quarter conference call may also be accessed by dialing
303-590-3000 or toll-free 800-405-2236, conference call ID 575530, between 6
p.m. CT on Thursday, April 29, until 6 p.m. CT on Thursday, May 6.

About CNS, Inc.

        CNS, based in Minneapolis,
is a growing company that designs and markets consumer health care products,
including Breathe Right®nasal strips, Breathe Right Snore
Relief throat spray, Breathe Right Vapor Shot! personal vaporizer
and FiberChoice®chewable fiber tablets. The company focuses on
products that address important consumer needs within the aging well/self care
market, including better breathing and digestive health. Its common stock is
listed on the Nasdaq National Market under the ticker symbol CNXS.
More information about CNS and its products is available at www.cns.com.

Some
of the information contained in this news release is forward-looking and subject to
certain business risks as described in the companys filings with the Securities and
Exchange Commission, including those referred to in its Annual Report on Form 10-K for the
year ended March 31, 2003. This news release contains forward-looking statements, which
involve risks and uncertainties.

---

CNS, Inc. Reports Fiscal 2004 Results
Page 5

CNS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts) (unaudtied)

|                                      | Three Months EndedMarch 31, |  | Twelve Months EndedMarch 31,
|------------------------------------- | --------------------------- |  | ----------------------------
|
|Net sales                             |                             |  | $                           
|Cost of goods sold                    |                             |  |                             
|                                      |                             |  |                             
|Gross profit                          |                             |  |                             
|                                      |                             |  |                             
|Operating expenses:                   |                             | 
|Advertising and promotion             |                             |  |                             
|Selling, general and administrative   |                             |  |                             
|                                      |                             |  |                             
|Total operating expenses              |                             |  |                             
|                                      |                             |  |                             
|Operating income                      |                             |  |                             
|Investment income                     |                             |  |                             
|                                      |                             |  |                             
|Income before income taxes            |                             |  |                             
|Income tax expense                    |                             |  |                             
|                                      |                             |  |                             
|Net income                            |                             |  | $                           
|                                      |                             |  |                             
|Diluted net income per share          |                             |  | $                           
|                                      |                             |  |                             
|Weighted average number of common and |                             | 
|potential common shares outstanding   |                             |  |                             
|                                      |                             |  |                             

CNS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands) (unaudited)

|                                           | March 31,2004 |  | March 31,2003
|------------------------------------------ | ------------- |  | -------------
|Current assets:                            |               |  |              
|Cash and marketable securities             |               |  | $            
|Accounts receivable, net                   |               |  |              
|Inventories                                |               |  |              
|Other current assets                       |               |  |              
|                                           |               |  |              
|Total current assets                       |               |  |              
|Long-term assets                           |               |  |              
|                                           |               |  |              
|Total assets                               |               |  | $            
|                                           |               |  |              
|Current liabilities                        |               |  |              
|Stockholders equity                       |               |  |              
|                                           |               |  |              
|Total liabilities and stockholders equity |               |  | $            
|                                           |               |  |              

---